Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO)

Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO)

The use of the direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban (DOACs) offers some major advantages over warfarin and other vitamin K antagonists (VKAs). One advantage is the possibility to use a fixed dose in normal-weight patients, overweight patients and patients with ob...

Full description

Bibliographic Details
Main Authors: David Mocini, Stefania Angela Di Fusco, Edoardo Mocini, Lorenzo Maria Donini, Carlo Lavalle, Andrea Di Lenarda, Carmine Riccio, Pasquale Caldarola, Leonardo De Luca, Michele Massimo Gulizia, Fabrizio Oliva, Domenico Gabrielli, Furio Colivicchi
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Journal of Clinical Medicine
Subjects:
obesity
atrial fibrillation
direct oral anticoagulants
DOACs
apixaban
dabigatran
Online Access:https://www.mdpi.com/2077-0383/10/18/4185

Internet

https://www.mdpi.com/2077-0383/10/18/4185

Similar Items